1Q EARNINGS: Vertex drops hepatitis C for cystic fibrosis focus
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals officially exited the hepatitis C market to focus on the company's cystic fibrosis therapies after telling Scrip earlier this year that it would divest the investigational antiviral drug VX-135 (scripintelligence.com, 30 January 2014).